2019 Annual Report
Making big health problems a smaller part of life
“Our role is to have a positive impact on the lives of patients with poorly understood diseases. It drives every decision we make.”
We’re taking on big health challenges to make them a smaller part of patients’ lives.
Grew to more than 425 colleagues worldwide
Marked the first full year of launch for ARIKAYCE® (amikacin liposome inhalation suspension) in the U.S.
Opened a new, state-of-the-art global HQ in Bridgewater, NJ
Filed for ARIKAYCE approval in Europe and Japan